Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review
- PMID: 25938992
- DOI: 10.7326/M14-2693
Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review
Abstract
Background: The role of fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) is not well-known.
Purpose: To assess the efficacy, comparative effectiveness, and harms of FMT for CDI.
Data sources: MEDLINE (1980 to January 2015), Cochrane Library, and ClinicalTrials.gov, followed by hand-searching references from systematic reviews and identified studies.
Study selection: Any study of FMT to treat adult patients with CDI; case reports were only used to report harms.
Data extraction: Data were extracted by 1 author and verified by another; 2 authors independently assessed risk of bias and strength of evidence.
Data synthesis: Two randomized, controlled trials (RCTs); 28 case-series studies; and 5 case reports were included. Two RCTs and 21 case-series studies (516 patients receiving FMT) reported using FMT for patients with recurrent CDI. A high proportion of treated patients had symptom resolution; however, the role of previous antimicrobials is unclear. One RCT comparing FMT with 2 control groups (n = 43) reported resolution of symptoms in 81%, 31%, and 23% of the FMT, vancomycin, or vancomycin-plus-bowel lavage groups, respectively (P < 0.001 for both control groups vs. FMT). An RCT comparing FMT route (n = 20) reported no difference between groups (60% in the nasogastric tube group and 80% in the colonoscopy group; P = 0.63). Across all studies for recurrent CDI, symptom resolution was seen in 85% of cases. In 7 case-series studies of patients with refractory CDI, symptom resolution ranged from 0% to 100%. Among 7 patients treated with FMT for initial CDI, results were mixed.
Limitation: Most studies were uncontrolled case-series studies; only 2 RCTs were available for analysis.
Conclusion: Fecal microbiota transplantation may have a substantial effect with few short-term adverse events for recurrent CDI. Evidence is insufficient on FMT for refractory or initial CDI treatment and on whether effects vary by donor, preparation, or delivery method.
Primary funding source: U.S. Department of Veterans Affairs.
Comment in
-
Fecal microbiota transplantation: what we know and what we need to know.Ann Intern Med. 2015 May 5;162(9):662-3. doi: 10.7326/M15-0609. Ann Intern Med. 2015. PMID: 25938997 No abstract available.
Similar articles
-
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2. Cochrane Database Syst Rev. 2023. PMID: 37096495 Free PMC article.
-
Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis.Am J Gastroenterol. 2013 Apr;108(4):500-8. doi: 10.1038/ajg.2013.59. Epub 2013 Mar 19. Am J Gastroenterol. 2013. PMID: 23511459
-
Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection.Aliment Pharmacol Ther. 2017 Sep;46(5):479-493. doi: 10.1111/apt.14201. Epub 2017 Jul 14. Aliment Pharmacol Ther. 2017. PMID: 28707337
-
Fecal microbiota transplant in patients with Clostridium difficile infection: A systematic review.J Trauma Acute Care Surg. 2016 Oct;81(4):756-64. doi: 10.1097/TA.0000000000001195. J Trauma Acute Care Surg. 2016. PMID: 27648772
-
Safety and efficacy of encapsulated fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review.Eur J Gastroenterol Hepatol. 2018 Jul;30(7):730-734. doi: 10.1097/MEG.0000000000001147. Eur J Gastroenterol Hepatol. 2018. PMID: 29688901
Cited by
-
The Role of the Intestinal Microbiome in Multiple Sclerosis-Lessons to Be Learned from Hippocrates.Biology (Basel). 2023 Nov 24;12(12):1463. doi: 10.3390/biology12121463. Biology (Basel). 2023. PMID: 38132289 Free PMC article. Review.
-
Alternatives to Antibiotics: A Symposium on the Challenges and Solutions for Animal Health and Production.Antibiotics (Basel). 2021 Apr 21;10(5):471. doi: 10.3390/antibiotics10050471. Antibiotics (Basel). 2021. PMID: 33918995 Free PMC article.
-
Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection.mSphere. 2024 Oct 29;9(10):e0070624. doi: 10.1128/msphere.00706-24. Epub 2024 Oct 8. mSphere. 2024. PMID: 39377587 Free PMC article.
-
New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota.Biomolecules. 2021 Mar 15;11(3):433. doi: 10.3390/biom11030433. Biomolecules. 2021. PMID: 33804226 Free PMC article. Review.
-
Cross-generational bacterial strain transfer to an infant after fecal microbiota transplantation to a pregnant patient: a case report.Microbiome. 2022 Nov 10;10(1):193. doi: 10.1186/s40168-022-01394-w. Microbiome. 2022. PMID: 36352460 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical